Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
2.335
-0.035 (-1.48%)
Jun 3, 2026, 12:02 PM EDT - Market open
Acumen Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Acumen Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $7.40. The average 1-year stock price forecast is 216.92% higher than the current stock price, while the lowest is $4.00 (+71.31%) and the highest is $10 (+328.27%).
Price Target: $7.40 (+216.92%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Acumen Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 6 | 6 | 6 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Maintains $8 | Buy | Maintains | $8 | +242.61% | May 15, 2026 |
| BTIG | BTIG | Buy Maintains $8 | Buy | Maintains | $8 | +242.61% | Apr 2, 2026 |
| Citi | Citi | Buy Maintains $4 | Buy | Maintains | $4 | +71.31% | Jan 30, 2026 |
| Lucid Capital | Lucid Capital | Buy Initiates $6 | Buy | Initiates | $6 | +156.96% | Dec 17, 2025 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Reiterates $10 | Buy | Reiterates | $10 | +328.27% | Dec 16, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.28
from -2.00
EPS Next Year
-1.44
from -1.28
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.13 | -0.75 | |
| Avg | -1.28 | -1.44 | |
| Low | -1.39 | -2.33 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.